Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MONTREAL, DEC. 31, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (PRIME OR THE COMPANY) ANNOUNCES A FIRST CLOSING OF ITS PREVIOUSLY ANNOUNCED NON-BROKERED PRIVATE PLACEMENT OFFERING OF UNITS OF THE COMPANY (THE UNIT OFFERING) FOR GROSS PROCEEDS OF $450,000. AS A RESULT, THE COMPANY ISSUED 7,500,015 COMMON SHARES IN THE CAPITAL OF THE COMPANY (THE COMMON SHARES) AND 7,500,015 WARRANTS. EACH WARRANT ENTITLES THE HOLDER TO PURCHASE ONE COMMON SHARE AT A PRICE OF $0.06 PER SHARE FOR A PERIOD OF THREE (3) YEARS FROM THE ISSUANCE DATE. NO FINDERS' FEE WAS PAID.

PRIME DRINK GROUP ANNOUNCES FIRST CLOSING OF PRIVATE PLACEMENT AND GRANT OF STOCK OPTIONS

MONTREAL, DEC. 17, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (PRIME OR THE COMPANY) ANNOUNCES THAT IT IS PROCEEDING WITH A NON-BROKERED PRIVATE PLACEMENT OFFERING OF UNITS OF THE COMPANY (THE UNITS) TO RAISE MINIMUM GROSS PROCEEDS OF $300,000 AND MAXIMUM GROSS PROCEEDS OF $5,000,000 (THE UNIT OFFERING).

PRIME DRINK GROUP ANNOUNCES PRIVATE PLACEMENT

CAMBRIDGE, MASS., DEC. 07, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THE PUBLICATION OF PHASE 1/2 CLINICAL DATA WITH PM359, THE COMPANY'S INVESTIGATIONAL AUTOLOGOUS HEMATOPOIETIC STEM CELL PRODUCT FOR P47PHOX CHRONIC GRANULOMATOUS DISEASE (CGD) IN THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM). THE DATA WILL ALSO BE PRESENTED IN A POSTER SESSION AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING, DECEMBER 6-9, 2025 IN ORLANDO, FLORIDA.

PRIME MEDICINE ANNOUNCES THE NEW ENGLAND JOURNAL OF MEDICINE PUBLICATION OF PM359 CLINICAL DATA FOR THE TREATMENT OF CHRONIC GRANULOMATOUS DISEASE

CAMBRIDGE, MASS., NOV. 25, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THAT ALLAN REINE, M.D.

PRIME MEDICINE TO PRESENT AT 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

CAMBRIDGE, MASS., NOV. 11, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THAT ALLAN REINE, M.D.

PRIME MEDICINE TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

-- NEW PRECLINICAL DATA FOR PM577 IN WILSON'S DISEASE (WD) TO BE PRESENTED AT AASLD; ON-TRACK TO FILE IND AND/OR CTA IN H1'26, WITH INITIAL CLINICAL DATA EXPECTED IN 2027 -- -- NOMINATED PM647 AS DEVELOPMENT CANDIDATE FOR ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD); ON-TRACK TO FILE IND AND/OR CTA IN MID-2026, WITH INITIAL CLINICAL DATA EXPECTED IN 2027 --

CORRECTION - PRIME MEDICINE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

PRIME MEDICINE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

CAMBRIDGE, MASS., NOV. 03, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THE APPOINTMENT OF MATTHEW HAWRYLUK, PH.D., M.B.A. AS CHIEF BUSINESS OFFICER (CBO). DR. HAWRYLUK WILL LEAD PRIME'S CORPORATE AND BUSINESS DEVELOPMENT INITIATIVES, CORPORATE STRATEGY, AND ALLIANCE MANAGEMENT FUNCTIONS, ADVANCING THE COMPANY'S EFFORTS TO EXPAND THE REACH OF PRIME EDITING THROUGH STRATEGIC PARTNERSHIPS AND COLLABORATIONS.

PRIME MEDICINE APPOINTS MATTHEW HAWRYLUK, PH.D., M.B.A. AS CHIEF BUSINESS OFFICER

CAMBRIDGE, MASS., OCT. 30, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THAT IT WILL HOST A VIRTUAL EVENT ON WEDNESDAY, NOVEMBER 12, 2025, TO DISCUSS ITS LIVER DISEASE FRANCHISE AND STRATEGY, WITH A FOCUS ON WILSON'S DISEASE.

PRIME MEDICINE TO HOST VIRTUAL KOL EVENT TO SHOWCASE WILSON'S DISEASE STRATEGY

CAMBRIDGE, MASS. , OCT. 07, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN TWO UPCOMING CONFERENCES: H. C.

PRIME MEDICINE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

MONTREAL, SEPT. 12, 2025 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (PRIME OR THE COMPANY) ANNOUNCES THAT FURTHER TO ITS NEWS RELEASES DATED JULY 30, AUGUST 15, AND AUGUST 29, 2025, THE COMPANY VOLUNTARILY APPLIED FOR AND THE COMPANY'S PRINCIPAL REGULATOR, THE BRITISH COLUMBIA SECURITIES COMMISSION (THE BCSC) GRANTED A MANAGEMENT CEASE TRADE ORDER (THE MCTO) DATED JULY 30, 2025, UNDER NATIONAL POLICY 12-203 MANAGEMENT CEASE TRADE ORDERS (NP 12-203) AND PROVIDED THE COMPANY WITH AN EXTENSION TO FILE ITS ANNUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2025, INCLUDING THE RELATED MANAGEMENT'S DISCUSSION AND ANALYSIS, AND RELATED CERTIFICATIONS ON OR BEFORE JULY 29, 2025 (COLLECTIVELY THE ANNUAL FINANCIAL FILINGS). THE DEADLINE HAS BEEN EXTENDED TO ON OR BEFORE SEPTEMBER 29, 2025.

Prime Medicine, Inc.

PRME

Price

Financial Reports

No items found.

Press Releases

Prime Medicine, Inc.

PRME.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PRME